Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

CRSP

C

CRISPR Therapeutics AG (CRSP)

NGM – Real vaqt narxi. Valyuta: USD

45.75

-1.80 (-3.79%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

45.40

-0.35 (-0.77%)

Bozordan keyin: Mar 27, 2026, 7:51 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.

Is CRISPR Therapeutics Stock a Buy Now?

Is CRISPR Therapeutics Stock a Buy Now?

CRISPR Therapeutics' lone approved product isn't generating much revenue yet. The company has made little clinical progress elsewhere in recent years.

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $46.93, representing a -1.59% change from its previous close.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.69, representing a -4.79% change from its previous close.

From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here

From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately.

Videolar

The Big 3: ASML, GOOGL, CRSP

Press-relizlar

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50 million aggregate principal amount of the notes.

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of the notes.

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D.

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY ® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated 2026 milestones. "Entering 2026, CRISPR Therapeutics is well positioned, with CASGEVY® gaining momentum, and multiple programs with encouraging data advancing rapidly through clinical trials across a diverse set of therapeutic areas,” said Samarth Kulkarni, Ph.D.